<DOC>
	<DOCNO>NCT01124838</DOCNO>
	<brief_summary>A study compare safety efficacy adalimumab compare . placebo adult inactive non-infectious intermediate uveitis , posterior uveitis , panuveitis .</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Subjects With Inactive Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject diagnose noninfectious intermediate , posterior , panuveitis . Subject ≥ 28 day prior Baseline visit inactive disease take ≥ 10 mg oral prednisone maintain inactive state fulfillment 3 follow criterion base Investigator 's clinical judgment Screening Baseline visit eye : Subject without active , inflammatory chorioretinal and/or inflammatory retinal vascular lesion . Subject anterior chamber cell grade ≤ 0.5+ accord Standardization Uveitis Nomenclature ( SUN ) criterion . Subject vitreous haze grade ≤ 0.5+ accord National Eye Institute ( NEI ) /SUN criterion . Subject oral prednisone 10 35 mg/day ( oral corticosteroid equivalent ) Baseline dose increase past 28 day decrease past 14 day . Subject must document history experience least one disease flare within 18 month Screening visit . This flare occur maximum 28 day taper oral corticosteroid therapy . Subjects previous , active latent tuberculosis ( TB ) . Only one TB test require allow subject study . Subjects either negative purify protein derivative ( PPD ) ( &lt; 5 mm induration ) negative QuantiFERON®TB Gold test ( interferongamma release assay ( IGRA ) equivalent ) eligible . Subjects repeat indeterminate QuantiFERON®TB Gold test ( IGRA equivalent ) result eligible . Note , one TB screen test allow require . A repeat QuantiFERON®TB Gold test ( IGRA equivalent ) permit PPD skin test positive . The TB screening test diagnostic test . In event negative TB screen test , result interpret context patient 's epidemiology , history , exam finding , etc . responsibility investigator determine patient previous , active latent tuberculosis . Under circumstance patient positive PPD result positive QuantiFERON®TB Gold test ( IGRA equivalent ) enter study . Subject isolate anterior uveitis . Subject confirm suspect infectious uveitis , include limited infectious uveitis due TB , cytomegalovirus ( CMV ) , Lyme disease , toxoplasmosis , human Tlymphotropic virus type 1 ( HTLV1 ) infection , Whipple 's disease , herpes zoster virus ( HZV ) herpes simplex virus ( HSV ) . Subject serpiginous choroidopathy . Subject corneal lens opacity precludes visualization fundus likely require cataract surgery duration trial . Subject intraocular pressure ≥ 25 mmHg ≥ 2 glaucoma medication evidence glaucomatous optic nerve injury . Subject best correct visual acuity ( BCVA ) less 20 letter ( ETDRS [ Early Treatment Diabetic Retinopathy Study ] ) least one eye Baseline visit . Subject intermediate uveitis panuveitis sign intermediate uveitis ( e.g . presence history snowbanking snowball ) symptoms and/or magnetic resonance imaging ( MRI ) finding suggestive demyelinate disease multiple sclerosis . All subject intermediate uveitis panuveitis sign intermediate uveitis ( e.g . presence history snowbanking snowball ) must brain MRI within 90 day prior Baseline visit . Subject previous exposure antitumor necrosis factor ( TNF ) therapy biologic therapy ( except intravitreal anti vascular endothelial growth factor ( VEGF ) therapy ) potential therapeutic impact noninfectious uveitis . Subject concomitant immunosuppressive therapy methotrexate , cyclosporine , mycophenolate mofetil equivalent drug mycophenolate mofetil ( e.g. , mycophenolic acid ) , azathioprine tacrolimus within 28 day Baseline discontinue immunosuppressive therapy include methotrexate , cyclosporine , mycophenolate mofetil equivalent drug mycophenolate mofetil ( e.g. , mycophenolic acid ) , azathioprine tacrolimus within 28 day Baseline . If enter study one concomitant immunosuppressive therapy , dose stable least 28 day prior Baseline visit within follow allowable dos Baseline visit : Methotrexate ( MTX ) ≤ 25 mg per week Cyclosporine ≤ 4 mg/kg per day Mycophenolate mofetil ≤ 2 gram per day equivalent drug mycophenolate mofetil ( e.g . mycophenolic acid ) equivalent dose approve Medical Monitor Azathioprine ≤ 175 mg per day Tacrolimus ( oral formulation ) ≤ 8 mg per day Subject Retisert® ( glucocorticosteroids implant ) within 3 year prior Baseline visit complication related device . Subject Retisert® ( glucocorticosteroid implant ) remove within 90 day prior Baseline visit complication related removal device . Subject receive intraocular periocular corticosteroid within 90 day prior Baseline visit . Subject proliferative severe nonproliferative diabetic retinopathy clinically significant macular edema due diabetic retinopathy . Subject neovascular/wet agerelated macular degeneration . Subject abnormality vitreoretinal interface ( i.e. , vitreomacular traction , epiretinal membrane , etc . ) potential macular structural damage independent inflammatory process . Subject cystoid macular edema unless retinal change persistent , residual stable define SUN criterion ( persistent &gt; 3 month duration ) . Subject receive Ozurdex® ( dexamethasone implant ) within 6 month prior Baseline visit . Subject receive intravitreal methotrexate within 90 day prior Baseline visit . Subject receive intravitreal antiVEGF therapy : within 45 day Baseline visit Lucentis® ( ranibizumab ) Avastin® ( bevacizumab ) ; within 60 day Baseline visit antiVEGF Trap ( Aflibercept ) . Subject systemic carbonic anhydrase inhibitor within 1 week prior Screening visit . Subject history scleritis . Subject cyclophosphamide within 30 day prior Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Uveitis</keyword>
</DOC>